🔗 Share this article

As America proceeds with sweeping revisions to its immunization guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations during the pandemic and has concentrated on alleged deaths after COVID-19 vaccination in her recent tenure at the FDA.

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders had intended to announce radical changes to the pediatric immunization program in December, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for benefit. This reveal has been postponed until the new year.

Rather than Vinay Prasad, Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the office this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a tighter collaboration between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending some childhood shot schedules in the US in order to be more like Denmark's approach, a society with universal health coverage and a citizenry approximately the population of Wisconsin’s.

To date comments, she has kept her attention on vaccines – usually the domain of Prasad, director of the FDA’s CBER – rather than medication approval.

Doubts Over Qualifications

The appointee has little discernible experience in drug development, approval processes or administrative roles, which has been typical for past directors of the CBER. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, noted Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who ran CBER have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“The public just zeroes in on the new drug program, but the off-patent medication office authorizes numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be looked after,” Dr. Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership element to the position, which manages more than 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Policies

Regarding inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among agency officials on immunizations, a press secretary said that the “inquiries rely on inaccurate presumptions”.

“Her experience aligns with the functions of her job,” the representative said, citing the time Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed rapid drug-approval program that allegedly worried her preceding directors. “How are these drugs being selected for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards less stringent oversight of all drugs, with the exception of vaccines.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, history, some experts said. She released a research paper using non-validated crowd-sourced reports to determine the rate of myocarditis following COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current administration included revising rules for novel immunizations and discontinuing “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has reportedly suggested excluding teenage boys from receiving COVID-19 vaccines.

“She is an complete dogmatist who starts off with her conclusions and tailors the evidence to fit the evidence in a highly misleading, dishonest manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|